Carregant...
Should we use the oral selective IP receptor agonist selexipag off-label in children with pulmonary arterial hypertension?
We discuss the currently available data on the use of the prostacyclin mimetic selexipag in children and adolescents with pulmonary arterial hypertension (PAH). Future indications may include transitioning from intravenous prostacyclin/prostacyclin analog to oral selexipag, and vice versa, or adding...
Guardat en:
| Publicat a: | Pulm Circ |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
SAGE Publications
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6161208/ https://ncbi.nlm.nih.gov/pubmed/30260767 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2045894018793580 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|